Dr. Roy C. Blank, MD, an expert in Internal Medicine and Clinical Nutrition, comments that “successful long-term pharmacological treatment of obesity has remained an elusive goal. Previous therapies that have produced adequate weight loss have produced unacceptable side effects. Fenfluramine and dexfenfluramine were associated with valvular heart disease and pulmonary hypertension. Sibutramine produced increased cardiovascular adverse events despite weight loss. The older agents are approved for short-term therapy only. Hopefully, the recently approved weight-loss medications will open a new era in obesity management. Chronic pharmacotherapy that produces weight-loss and reduces adverse cardiovascular outcomes represents the optimal therapeutic goal. If the new and future medications achieve this dual goal of weight loss and cardiovascular-event reduction, perhaps non-surgical treatment of obesity will achieve the success that is now seen with hypertension management.”

REFERENCES
1. Obesity. Centers for Disease Control and Prevention. (2012). Retrieved from http://www.cdc.gov/chronicdisease/resources/publications/aag/obesity.htm  Accessed July 18, 2012


Continue Reading

2. Obesity Fact Sheet. World Health Organization (2012). Retrieved from http://www.who.int/mediacentre/factsheets/fs311/en/index.html  Accessed July 18, 2012

3. Prescription Medications for the Treatment of Obesity. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. (2012). Retrieved from http://win.niddk.nih.gov/publications/prescription.htm  Accessed July 19, 2012

4. Phentermine [package insert] Akrimax Pharmaceuticals LLC., Cranford, NJ.

5. Cercato C, Roizenblatt VA, Leança CC, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond). 2009 Aug;33(8):857-65. Epub 2009 Jun 30.

6. Sibutramine. Medline Plus. (2012). Retrieved from http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601110.html  Accessed July 19, 2012.

7. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998 Jul 18;352(9123):167-72.

8. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. New England Journal of Medicine. 2010; 363:245-256

9. Qsymia [package insert]. VIVUS, Inc., Mountain View, CA; 2007.

10. Allison DB, Gadde KM, Garvey WT, et al. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obesity (Silver Spring). 2012.

11. Gadde KM, Allison DB, Ryan, DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 30;377(9776):1494

12. National Institutes of Health, National Heart, Lung, and Blood Institute. Therapeutic guidelines: The Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults; 2000. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf

13. Xenical [package insert]. Genentech, Inc., South San Francisco, CA; 2012.

14. Alli [product labeling]. GlaxoSmithKline, Research Triangle Park, NC; 2012. Retrieved from http://www.empr.com/alli/obesity/drug/6019/

15. Adipex-P [package insert]. Teva Pharmaceuticals USA, Sellersville, PA; 2012.

16. Phendimetrazine tartrate extended-release tablets [package insert]. Sandoz, Princeton, NJ;2012.

17. Diethylpropion HCl [package insert]. Watson Laboratories, Inc.,Corona, CA; 2012.

18. Diethylpropion HCl extended-release tablets[package insert]. Watson Laboratories, Inc.,Corona, CA; 2012.